Treatment Action Group welcomes the Global Drug Facility / Stop TB Partnership's negotiation of what amounts to a 32% savings on bedaquiline, the backbone of improved, all-oral regimens for treating drug-resistant TB.
Pipeline Report provides an overview of research and provides an overview of research and development of innovations for diagnosing, preventing, treating, and curing HIV, hepatitis C virus (HCV), and tuberculosis (TB).
Tomorrow, Treatment Action Group (TAG) will be observing and honoring Juneteenth—a commemoration of the end of slavery in the United States—through a day of solidarity, actions, and reflection.
On this podcast, Dr. Madhukar Pai describes the ways that the COVID-19 pandemic has delayed and limited access to TB diagnostic testing, and how all stakeholders must step-up efforts to mitigate these impacts and ensure that TB diagnostic testing is not abandoned in the response to COVID-19.
2019 was a year of significant progress against HIV, tuberculosis (TB), and hepatitis C virus (HCV). We shaped policy and legislation to end these conditions, secured increased funding to do so at various levels of government, and stood up for the rights of affected communities.
Treatment Action Group (TAG) joins partners, activists, and communities around the U.S. and the world in decrying violence against Black people and those who stand in solidarity with them.
ICAP at Columbia, TAG, and the COVID-19 Working Group – New York presented this webinar on May 13, 2020.
The COVID-19 pandemic is a global health emergency that may demand new, safe, and expedited ways of conducting ethical research to find the solutions we need, including a safe and effective vaccine.
Realizing the Right to Science: When we started to put together this issue of TAGline, we had no idea that COVID-19 was about to make its appearance and wreak havoc on every country of the world.
Treatment Action Group (TAG) and the PrEP4All Collaboration welcome results from randomized controlled trials of therapies for COVID-19, but are seriously concerned about claims that data from a National Institutes of Allergy and Infectious Diseases (NIAID) study of the Gilead drug remdesivir...